A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors
Jia Zhou, Camille Gelot, Constantia Pantelidou, Adam Y. Li, Hatice Yücel, Rachel E. Davis, Anniina Färkkilä, Bose Kochupurakkal, Aleem Syed, Geoffrey I. Shapiro, John A. Tainer, Brian S. J. Blagg, Raphaël Ceccaldi, Alan D. D’Andrea
Topics & Concepts
RAD51Homologous recombinationBiologyPoly ADP ribose polymeraseCancer researchPolymeraseIn vivoMolecular biologyDNA damagePARP inhibitorDNAGeneticsDNA Repair MechanismsPARP inhibition in cancer therapyCancer therapeutics and mechanisms